Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
More Weakness For CSL
Jul 12 2011
The TechWizard reports CSL shares have broken below 20 M/A indicating more weakness is on the cards.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Jul 11 2011
Weekly update on recommendation, target price, and earning forecast changes.
First Royalties Drawing Nearer For Starpharma
Jul 04 2011
The stockbroker formerly known as Southern Cross Equities (now Bell Potter) has reiterated its Speculative Buy rating on Starpharma.
Top Ten Weekly Recommendation, Target Price, Earning Forecast Changes
Jul 04 2011
Weekly update on recommendation, target price, and earning forecast changes.
Too Early To Buy CSL?
Jul 01 2011
While recent share price weakness has improved the value on offer, Morgan Stanley suggests it remains too early to be a buyer of CSL.
Icarus Signal New Entries For Today
Jun 03 2011
Daily update on share prices and consensus price targets.
Morgan Stanley Breaks Consensus And Says Buy Sigma
Jun 02 2011
While brokers in the FNArena databse favour Sell ratings on Sigma Pharmaeceutical, Morgan Stanley has gone against the trend and upgraded to an Overweight rating.
Return Of The Living Dead
Jun 01 2011
This story was first published two days ago in the form of an email sent to paying members. By Rudi…
Starpharma, Rising Star?
May 25 2011
Starpharma should generate first revenues from its VivaGel product this year and Southern Cross sees further upside as the company continues to develop its dendrimer technology.
REVA Medical: Affairs Of The Heart
May 24 2011
REVA Medical is developing bioresobable stents for treating coronary artery disease and Southern Cross rates the stock a Spec Buy.
Analyse The Market From A Different Angle
Latest News
| 1 |
ASX Winners And Losers Of Today – 07-07-25Jul 07 2025 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Jul 07, 2025Jul 07 2025 - Daily Market Reports |
| 3 |
Investing In AI & Growth; A Personal ExperienceJul 07 2025 - International |
| 4 |
Australian Listed Real Estate Tables – 07-07-2025Jul 07 2025 - Weekly Reports |
| 5 |
Tasmea’s Secret Sauce For Higher-Margin GrowthJul 07 2025 - Small Caps |